Research
Hormonal
Semaglutide 2.4 mg administered once weekly induces significant body weight reduction (>10% in ~69% of patients) in non-diabetic adults with obesity when used as an adjunct to lifestyle programs.
For non-diabetic adults with obesity, semaglutide 2.4 mg taken once weekly, combined with lifestyle changes, can lead to an average 14.9% body weight loss over 68 weeks. This is significantly more effective than placebo. Be prepared for potential gastrointestinal side effects like nausea, which are common but often subside.
StrongSupportsVERY_HIGH confidence
In non-diabetic individuals overweight or obese, 68 weeks of treatment with semaglutide (2.4 mg QW), decreased body weight by 14.9% relative to 2.4% in placebo treated controls (28). Impressively, 86.4% of patients treated with semaglutide showed weight loss >5% (vs. 31.5% in placebo controls), while 69.1% (vs. 12.0% in placebo controls) lost >10%...
Why this rating
Based on a large-scale clinical trial (68 weeks, n=large implied by % stats) with FDA approval.
Source
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan et al. · Frontiers in Endocrinology · 2022
narrative_reviewCited 142×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →